Blincyto (blinatumomab) Letter of Medical Necessity
Blincyto (blinatumomab) is a bispecific T-cell engager for B-cell ALL, used in both relapsed/refractory and MRD-positive settings. Prior authorization requires detailed disease documentation and MRD testing results.
FDA-Approved Indications
- ● B-cell precursor acute lymphoblastic leukemia (ALL) in first or later remission with MRD ≥0.1%
- ● relapsed or refractory B-cell precursor ALL
Why Blincyto Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. MRD status not documented (for MRD+ indication)
- 2. CD19 expression not confirmed
- 3. Philadelphia chromosome status not documented
- 4. Hospitalization requirement for first cycle not addressed
What to Include in a Blincyto Letter of Medical Necessity
Document B-cell precursor ALL diagnosis, CD19 expression by flow cytometry, Philadelphia chromosome/BCR-ABL status, MRD status by flow cytometry or PCR (≥0.1% for MRD+ indication), remission status, prior therapy lines, and plan for hospitalization during first cycle.
Key clinical evidence to cite:
- ✓ BLAST Phase 2 trial (MRD+ ALL)
- ✓ TOWER Phase 3 trial (R/R ALL) — superior OS vs chemotherapy
- ✓ E1910 Phase 3 — improved OS when added to consolidation in MRD+ ALL
Relevant guidelines:
- 📖 NCCN ALL Guidelines
- 📖 ASH 2024 ALL Treatment Recommendations
Blincyto Prior Authorization Criteria
Standard criteria across major US payers for Blincyto. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Blincyto
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Blincyto Prior Authorization FAQ
Why was my Blincyto prior authorization denied?
The most common denial reasons for Blincyto are: MRD status not documented (for MRD+ indication); CD19 expression not confirmed; Philadelphia chromosome status not documented; Hospitalization requirement for first cycle not addressed.
What should a Blincyto Letter of Medical Necessity include?
Document B-cell precursor ALL diagnosis, CD19 expression by flow cytometry, Philadelphia chromosome/BCR-ABL status, MRD status by flow cytometry or PCR (≥0.1% for MRD+ indication), remission status, prior therapy lines, and plan for hospitalization during first cycle.
Which payers cover Blincyto?
Blincyto is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.